Navigation Links
Sirrus Expanded Bench Facility Increases Production Of Monomers
Date:4/15/2019

Sirrus, Inc., a developer of novel electron-deficient monomers and oligomers, has completed construction of a $2 million bench plant expansion to increase production of methylene malonate monomers and oligomers.

The expanded bench facility represents an important step in the design and construction of Sirrus’ full-scale production facility, which is scheduled to break ground in 2019. “The expanded facility makes use of equipment that is scalable. This affords our engineering partners access to continuous process data, testing of control strategies and demonstration of in process stabilization. This combination provides extreme confidence in producing these monomers in commercial quantities at our desired product specifications,” says Jeff Uhrig, Sirrus CEO.

The pilot facility also gives Sirrus and its development partners access to larger quantities of the company’s methylene malonate monomers. This will allow partners to conduct line trials and customer qualification, an important step towards advancing commercial offtake discussions. When operating continuously, the expanded facility will be able to produce up to two tonnes per month of monomer.

Sirrus’ core monomer and macromer products—Chemilian™ and Forza™—have near-term applications in adhesives, sealants and coatings. Other promising applications for methylene malonate technology are supported by the company’s growing intellectual property portfolio, which now consists of 74 globally issued patents.

Learn more at http://www.sirruschemistry.com.

About Sirrus
Sirrus Inc. develops and supplies unique chemical building blocks for the next generation of high performance coatings, adhesives, sealants and composites. Our patented technology focuses on methylene malonate monomers and oligomeric crosslinkers that can polymerize anionically at ambient temperatures. Sirrus works with development partners in the automotive, electronics, packaging and consumer goods industries to deliver sustainable products that will enhance energy efficiency, safety and performance. Sirrus Inc. is a wholly owned subsidiary of Nippon Shokubai, a global chemical company and leading supplier of acrylates, specialty monomers, functional polymers and catalysts. For more information, visit http://www.sirruschemistry.com.

Read the full story at https://www.prweb.com/releases/sirrus_expanded_bench_facility_increases_production_of_monomers/prweb16240917.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Ribbon Cutting and Open House at Milwaukee Area Technical College on Oct. 17 to Spotlight New CNC Swiss Machinery and Expanded Instructional Capacity
2. RenovoRx Announces FDA Clearance for Expanded Labeling
3. Personal Genome Diagnostics Announces Expanded Cancer Testing Contract with U.S. Department of Veteran Affairs
4. Integrated Service Solutions, Inc. Announces Expanded Scope of Accreditation by A2LA
5. Neurophotonics Accepted Into Science Citation Index Expanded
6. Proove Biosciences Launches Expanded Drug Metabolism Profile to Help Doctors Prescribe Heart Medications with Greater Precision
7. New Journal Articles Cite Expanded Use of BioLife Solutions Products in Clinical Cell Therapy Applications
8. BioBridge Global, StemBioSys Announce Expanded Collaboration to Provide Human Umbilical Cord Blood Stem Cells for Research
9. ProMIS Neurosciences Announces Expanded License Agreement with The University of British Columbia
10. Treato Launches Social Media Application for an Expanded View of the Patient Pulse
11. Prometheus Research Announces $1M in Expanded Funding From Public and Private Sectors, Sees Broader Applications for Their Integrated Registry Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2019)... ... July 11, 2019 , ... At the most recent stem ... to eight military Veterans under the R3 Heroes Program. The Veterans included individuals and ... Heroes Program allow anyone to nominate a military Veteran, teacher or first responder to ...
(Date:6/18/2019)... NEW YORK and SOMERSET, N.J. (PRWEB) , ... ... ... and Catalent Biologics, today announced that they have entered into an agreement for ... therapy product candidates, IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... add 80 of its scientific journals to DeepDyve’s rental service for peer-reviewed journals. ... continually expanding library of more than 20 million articles, sourced from more than ...
(Date:5/31/2019)... ... May 29, 2019 , ... For many years, the primary forms ... cancer demand breakthrough therapies. Advances in immuno-oncology have led to the advent of Chimeric ... with engineered T cell receptors known as “CARs”. The CAR enables the final product ...
Breaking Biology Technology:
(Date:8/14/2019)... , ... August 14, 2019 , ... Join Jonathan Riek, ... session on Tuesday, September 10, 2019 at 1pm EDT to learn about two ... effective management. , NAFLD is the most common diffuse liver disease, with a ...
(Date:8/9/2019)... ... ... With a demand in healthcare to lower unneeded emergency room visits and ... (UCC) in the coming years, according to a new report on the industry by ... , is a detailed look at the current state of these healthcare outlets, including ...
(Date:8/6/2019)... FALLS, Wis. (PRWEB) , ... August 06, 2019 ... ... to health, sustainability, and environmental concerns. One plant-based food in particular quickly entered ... their animal-meat counterparts, product developers use a thermogelling and emulsifying ingredient such as ...
Breaking Biology News(10 mins):